Tracers / [68Ga]S02-GIP-T4

[68Ga]S02-GIP-T4

Also written as [Ga-68]S02-GIP-T4

Radionuclide: Ga-68 t½ 67.71 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Metabolic drug-receptor occupancy imaging (GLP-1R, GIPR)

What it is

Compound class: DOTA-conjugated peptide (GIP receptor-targeting peptide, DOTA-S02-GIP-T4)
Target / mechanism: GIP receptor (GIPR) PMID 41274021
Clinical application: Type 2 diabetes and obesity (assessing incretin receptor drug occupancy) PMID 41274021
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	DOTA-S02-GIP-T4 Sanofi	41274021 2025 EBioMedicine

Need this precursor?We can point you to suppliers for [68Ga]S02-GIP-T4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41274021. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41274021: 'unlabelled DOTA-S02-GIP-T4 (generated by custom in-house Solid Phase Peptide Synthesis (SPPS) by Sanofi)'. | Stage 28: added indication(s) end-receptor-occupancy from consolidated missing-rubric review.